KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

OLFEN-75 SR DEPOTABS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

DICLOFENAC

 

MANUFACTURER:

MEPHA LTD.

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

X

 

INDICATIONS:

Arthritis, osteoarthritis

Arthritis, rheumatoid

 

SIDE EFFECTS:

abdominal pain

acute generalized exanthematous pustulosis (AGEP)

agranulocytosis

anaphylactoid reactions

anemia

aplastic anemia

aseptic meningitis

azotemia

blurred vision

confusion

conjunctivitis

constipation

corneal edema

corneal erosion

diarrhea

dizziness

dyspepsia

dysphagia

elevated hepatic enzymes

erythema multiforme

esophageal stricture

esophageal ulceration

esophagitis

fluid retention

gastritis

GI bleeding

GI perforation

headache

heart failure

hematuria

hemolytic anemia

hepatic necrosis

hepatitis

infection

interstitial nephritis

iritis

jaundice

keratitis

melena

nausea/vomiting

nephrotic syndrome

ocular irritation

ocular pain

odynophagia

pancreatitis

pancytopenia

peptic ulcer

peripheral edema

photophobia

platelet dysfunction

porphyria

proteinuria

pruritus

purpura

pyrosis (heartburn)

renal failure (unspecified)

renal papillary necrosis

Stevens-Johnson syndrome

tinnitus

urticaria

visual impairment

xerophthalmia

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

acute bronchospasm

alcoholism

anemia

anticoagulant therapy

asthma

benzyl alcohol hypersensitivity

breast-feeding

chemotherapy

children

coagulopathy

contact lenses

corticosteroid therapy

dehydration

dental disease

dental work

diabetes mellitus

edema

elderly

exfoliative dermatitis

GI bleeding

GI disease

heart failure

hemophilia

hepatic disease

hypertension

hypovolemia

immunosuppression

jaundice

labor

nasal polyps

neutropenia

ocular exposure

ocular surgery

peptic ulcer disease

porphyria

pregnancy

renal disease

renal failure

renal impairment

rheumatoid arthritis

skin abrasion

sunlight (UV) exposure

surgery

systemic lupus erythematosus (SLE)

thrombocytopenia

tobacco smoking

ulcerative colitis

 

ADULT DOSE:

Antirheumatic (nonsteroidal anti-inflammatory) -Oral, 75 or 100 mg once a day, in the morning or evening, or 75 mg two times a day, in the morning and evening. Note: The extended-release dosage form is not intended as initial therapy; the daily maintenance dose should be determined using an immediate- or delayed-release formulation. The extended-release dosage form may then be used, if desired, provided that the required dose can be achieved with the available strengths.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Safety and efficacy have not been established.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT